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Summary
A library of dimerization inhibitors of HIV-1 protease is
described based on crosslinked interfacial peptides.
The 54 component library was designed to contain
two modifications to the starting structure, one each
in the Northern and Southern fragments. A rapid syn-
thesis and in situ screening method in microtiter
plates was developed to facilitate the generation and
evaluation of the library members. More than 90% of
the doubly modified agents were more potent than
their respective singly mutated parent compounds,
and five of the most potent dimerization inhibitors of
HIV-1 protease described to date were identified. The
free energy of binding for the combined two modifica-
tions was generally found to be additive, demonstrat-
ing the predictive value of earlier libraries.
Introduction
In the search for novel inhibitors to block HIV infection,
HIV protease (PR) is a target of great importance. In ad-
dition to the many classes of agents that target the ac-
tive site [1–3], inhibitors that bind the dimeric interface
of PR have been identified [4]. In the latter category,
crosslinked interfacial peptides of PR have been shown
to inhibit the dimerization and activity of PR [5, 6]. Re-
cently, a library of agents, based on the structure of in-
hibitor 1, was studied [7]. The library was composed of
single amino acid modifications to 1, and fairly potent di-
merization inhibitors were identified.
To improve potency, simultaneous and multiple
modifications to inhibitor 1 would be desirable. A num-
ber of the best, single amino acid changes to 1 could
be used to enhance diversity with the potential to im-
prove efficacy. Even a small library of this sort, how-
ever, is time consuming to synthesize, purify, and
screen. The in situ synthesis and screening of sulfo-
transferase [8], a-fucosidase [9], and active site HIV
PR inhibitors [10] has been reported by Wong and co-
workers. In these studies, an amide bond was formed
as the last step of the inhibitor synthesis in microtiter
plates, and the agent was screened without purifica-
tion. A similar amide bond-forming reaction was envi-
sioned for the preparation of HIV PR dimerization inhib-
itors. Herein we describe a synthesis and in situ
screening method to evaluate a focused library of
agents based on inhibitor 1 that contain double modifi-
cations to the structure.
*Correspondence: chml@purdue.eduResults and Discussion
Selection of Library Components
Compound 1 (Figure 1) is composed of a Northern tri-
peptide fragment and a Southern dipeptide fragment
linked at their amino termini by an aliphatic tether. Three
modifications were chosen for each of the five positions
within 1, based on the previous library of single amino
acid changes (Figure 1). Since aromatic and cyclic ali-
phatic moieties were found to be essential at positions
1 and 5 of compound 1, the most effective side chains
were included in the library design [7]. Likewise, the
branched aliphatic side chains that were found to be
most effective within position 2 were accommodated
as library components. Positions 3 and 4 both preferred
a phenyl side chain; however, to improve the solubility of
members of the library, branched aliphatic and more hy-
drophilic groups were included. Two simultaneous mu-
tations were planned within the structure of 1, one in
the Northern fragment and one in the Southern frag-
ment. The combination of nine Northern components
and six Southern components, therefore, would lead to
54 unique library members.
In Situ Synthesis and Screening of Library
Previous syntheses of crosslinked interfacial peptide in-
hibitors of HIV PR dimerization have been carried out in
solution and on solid support [5, 6]. In both cases, exten-
sive purifications were performed prior to testing. It
would be of interest to develop methods in which the fi-
nal compounds could be tested in situ, because com-
pound libraries are time intensive to purify. Recently,
Wong and coworkers described libraries of compounds
by using an in situ amide bond-forming reaction be-
tween the amine and carboxylic acid components with
HBTU coupling [8–10]. The free acid form of compounds
such asA (Figure 2) had poor solubility. Therefore, it was
expeditious to generate Northern fragments (A) with the
NHS-ester intact for reaction with the Southern dipep-
tide amines (B) (Figure 2). In a typical reaction, solutions
of the Northern fragments (A) in DMSO in microtiter
plates were treated with solutions of the Southern di-
peptides in DMSO (B, 4 equivalents) and DIEA. Reac-
tions were monitored by HPLC and mass spectrometry
for complete consumption of A (10–12 hr), and, with
the exception of residual B, NHS, and DIEA, the desired
material was formed in greater than 95% purity.
For in situ screening, it was essential to determine if
the reaction byproducts and excess reagents had inhib-
itory activity. All Southern dipeptides were tested
against HIV PR up to a concentration of 300 mM, and
less than 10% inhibition was observed in all cases. Like-
wise, NHS and DIEA at concentrations of 300 mM had no
effect on HIV PR activity, nor did combinations of these
two reagents with the Southern peptides. These data
were a good indication that the crude library compo-
nents would have similar activity to those that were pu-
rified. To test this hypothesis, we purified ten of the
library members to homogeneity by HPLC and com-
pared their IC50 values to those of their in situ-generated
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422Figure 1. The Modifications Chosen at the
Five Positions of Compound 1 for the Double
Mutation Studycounterparts (see the Supplemental Data available with
this article online). In the latter case, the reaction mix-
tures were diluted to 400 mM in the desired compound
and transferred to a new microtiter plate. The fluoro-
genic assay of Toth and Marshall [11] was used to deter-
mine inhibitory activity against HIV PR. In all cases, the
IC50 values obtained were either within experimental er-
ror or were within 10% of each other for the purified or in
situ-generated compounds. The success of this experi-
ment prompted us, therefore, to evaluate all 54 com-
pounds in situ against HIV PR. Both compound 1 and
Thx1 were reevaluated concurrently with the 54 com-
pound library, and the values obtained were found to
be within the errors of the previously reported values [6].
Interesting trends can be discerned from analysis of
the inhibitory activity of the doubly modified library
members (Table 1; Figure 3). First, all of the inhibitors
of the library were more potent than the starting com-
pound 1 (IC50 of 5.5 mM, Ki of 3.0 mM). Also, more than
90% of the double-modified compounds were either
more potent or equipotent as compared to their singly
mutated parent compounds. Overall, the most improved
compound was Chg1Nal5; this compound was 10-fold
and 9-fold more potent than its two parent inhibitors
with single mutations (Chg1 and Nal5, respectively).
The most improved series of compounds was found
within position 5. Each of the single mutant inhibitors
(Cha5, Hfe5, and Nal5) was a moderately potent agent
that was improved, on average, 7.5-fold with an addi-
tional modification to its structure. The least improved
series based on the Northern fragments included those
compounds containing Thx in position 1; for instance,equivalent activity was obtained with Thx1Hfe5,
whereas a 1.7-fold increase was observed with
Thx1Nal5, as compared to Thx1. Thx1 was already a po-
tent single mutation, and modification to the other four
positions had less of an effect overall. Likewise, addi-
tional mutations to the Paf4 compound were less pro-
ductive than that observed for the other Southern pep-
tide changes. The three most potent agents from the
double mutation studies, however, were those that con-
tained Thx1 in addition to mutations at Paf4, Cha5, and
Nal5.
Seven of the more potent agents from the in situ
screening were analyzed further to determine Ki values
and their mechanism of inhibition. All compounds were
found to be dimerization inhibitors by the kinetic method
of Zhang and Poorman [12], as a plot of Eo/v
1/2 versus
v1/2 led to parallel lines for HIV PR with and without inhib-
itor (Figure 4). Additionally, five compounds were found
to be among the most potent dimerization inhibitors of
HIV PR that have been reported to date, with Ki values
between 30 and 50 nM (Table 2).
We were interested in determining the predictive value
of our single mutant library for future multiple mutation
libraries. Therefore, we compared the Ki values obtained
for the doubly modified inhibitors to the Ki values for
each of their two parent compounds to determine
what effect the two simultaneous changes had on inhibi-
tion. We calculated the increase in potency that should
be observed, as compared to inhibitor 1, if the two mod-
ifications had an additive effect (Table 3). These data
were then compared to the observed increase in po-
tency over compound 1. In three cases, the value that
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of binding, was within experimental error of the actual in-
crease in potency over compound 1. In two cases, the
actual value was within 10%–20% of the calculated
increase in potency, and, in two cases, there was a
major discrepancy with the predicted value. Thx1Paf4
Figure 2. Microtiter Plate Synthesis
(A) Schematic of the reaction of the acylated Northern peptide fragments and Southern peptide fragments in a microtiter plate format.
(B) Structure of the nine acylated Northern fragments and six Southern fragments used to compose the doubly modified library.
Table 1. IC50 Values, mM, of the Doubly Modified Library Members against HIV-1 PR
Southern
Position 4 Position 5
Northern CmeO2 (2.9) Paf (0.6) Met (2.7) Cha (3.7) Hfe (4.4) Nal (2.9)
Position 1 Thx (0.4) 0.46 0.24 0.41 0.24 0.4 0.23
Bip (1.09) 0.51 1.02 0.46 0.69 0.64 0.51
Chg (3.1) 0.58 0.90 0.67 0.55 0.53 0.31
Position 2 Cha (1.6) 0.84 0.67 1.34 0.63 0.77 0.53
Ile (2.5) 1.17 0.97 1.67 0.77 1.24 0.61
Chg (0.68) 0.58 0.71 0.48 0.58 0.65 0.37
Position 3 Leu (0.87) 0.47 0.33 0.65 0.54 0.51 0.39
Val (1.3) 0.48 0.32 0.58 0.41 0.53 0.38
Met (1.2) 0.47 0.53 0.58 0.50 0.57 0.37
Modifications to compound 1 in both the Northern (positions 1–3) and Southern (positions 4 and 5) fragments are indicated. IC50 values (mM) for
the single change at that position are shown in parentheses. Values with error bars are reported in the Supplemental Data. Nonstandard amino
acids are the following: Thx, thyroxine; Bip, biphenylalanine; Chg, cyclohexylglycine; Cha, cyclohexylalanine; CmeO2, methylcysteinesulfone;
Paf, 4-aminophenylalanine; Hfe, homophenylalanine; Nal, naphthylalanine.
Chemistry & Biology
424displayed a negative synergistic effect, whereas a signif-
icant positive synergistic effect was found with the most
improved agent, Chg1Nal5. The observed negative syn-
ergistic effect could potentially be due to one mutation
causing a change in binding at the site of the second
side chain mutation, or it could be due to stabilization
Figure 3. Activity Enhancement of Library Members
The enhancement (x-fold) of activity of each member of the library
as compared to compound 1.
Figure 4. Zhang-Poorman Assay of Compounds Ile2Cha5, Val3-
Paf4, and Thx1Nal5
Hyphen, uninhibited HIV-1 PR; diamond, 0.7 mM Ile2Cha5; triangle,
0.3 mM Val3Paf4; square, 0.25 mM Thx1Nal5 (5–40 nM HIV-1 PR,
25 mM substrate).of the unbound form of the doubly mutated compound,
perhaps by p-p interactions within the biarylether and
the aniline side chains of Thx1Paf5.
Significance
We have developed a microtiter plate-based synthetic
strategy for our library of doubly modified HIV PR di-
merization inhibitors that is high yielding. The excess
reagents and byproducts of the reaction were found to
have little effect on HIV PR at high concentration. All of
the library entries weremore potent than starting com-
pound 1, and more than 90% of the compounds were
more potent than their respective singly modified par-
ent inhibitors. Some of the more potent agents were
further analyzed and were found to be dimerization in-
hibitors. For this latter group, the binding free ener-
gies for the two combined mutations were found to
be additive, with two important exceptions. Finally,
five of the most potent HIV PR dimerization inhibitors
reported to date were identified [13, 14] as a result of
this in situ synthesis and screening method.
Table 2. Ki Values of the Doubly Modified Library Members
against HIV-1 PR
Northern Component Southern Component
Ki (nM)Position Residue Position Residue
1 Thx 4 Paf 29.3 6 0.2
1 Thx 5 Nal 29.2 6 0.3
1 Thx 5 Cha 35.1 6 0.5
1 Chg 5 Nal 65.2 6 2.3
2 Ile 5 Cha 143 6 1.4
3 Leu 4 Paf 40.1 6 0.7
3 Val 4 Paf 51.0 6 0.5
Modifications to compound 1 in both the Northern (positions 1–3)
and Southern (positions 4 and 5) fragments are indicated. Ki values
are expressed as mean 6 standard deviation from triplicate mea-
surements.
Table 3. Calculated Increases in Potency of the Doubly Modified
Inhibitors if the Two Modifications Had an Additive Effect, as








IncreasePosition Residue Position Residue
1 Thx 4 Paf 490 6 50 103 6 4
1 Thx 5 Nal 105 6 10 102 6 4
1 Thx 5 Cha 117 6 17 86 6 4
1 Chg 5 Nal 7 6 1 46 6 3
2 Ile 5 Cha 17 6 3 21 6 1
3 Leu 4 Paf 95 6 17 75 6 3
3 Val 4 Paf 40 6 7 59 6 2
Modifications to compound 1 in both the Northern (positions 1–3)
and Southern (positions 4 and 5) fragments are indicated. All values
are expressed as mean 6 standard deviation from triplicate mea-
surements.
a Expected increases were calculated by adding the changes in the
free energy of binding (relative to compound 1) of the two respective
individual mutants.
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Materials
HIV-1 PR was purchased from Bachem Biosciences (affinity purified
grade). Amino acids, coupling reagents, and resins were purchased
from either Advanced Chemtech or ChemImpex. All other reagents
were purchased from Aldrich and were used without purification.
General Procedure for Synthesis of Northern
Peptide Fragments
The Northern tripeptide fragments were synthesized on the Rink
amide resin by using a fluorenylmethoxycarbonyl (Fmoc)-based
strategy with no side chain protection except for that of Fmoc-
Thr(OtBu)-OH. HBTU (O-benzotriazole-N,N,N0,N0-tetramethyluro-
niumhexafluorophosphate) (3 equivalents) and HOBt (1-hydroxy-
benzotriazole) (3 equivalents) were used as the coupling reagents
with DIEA (3 equivalents) in (DMF) (3.5 ml per 100 mg resin) at
room temperature for 3 hr. Upon completion of each coupling
step, the terminal Fmoc group was removed with 20% piperidine
in DMF (3.5 ml per 100 mg resin), followed by the next coupling re-
action. Upon completion of the synthesis, the tripeptides were
cleaved from the resin with a trifluoroacetic acid (TFA) cocktail con-
taining 95% TFA, 2.5% triisopropylsilane, and 2.5% water (1.5 ml per
100 mg resin) for 2 hr. The mixtures were filtered through glass wool,
and the filtrates were concentrated in vacuo to remove the TFA. The
peptides were precipitated with cold ether and stored at 280ºC for
12 hr to insure complete precipitation. The precipitates were col-
lected via centrifugation and were used in the next step without
purification.
General Procedure for Synthesis of N-Hydroxysuccinimide-
Activated, Acylated Northern Peptide Fragments
The crude Northern tripeptide fragments (A, Figure 2) (0.072 mmol) in
DMF/CH2Cl2 (1:1, 4 ml) were treated with DIEA (4 equivalents) and
hexadecanedioic acid bis-(N-hydroxysuccinimide) ester (4 equiva-
lents) at room temperature, and the mixture was allowed to stir for
12 hr. Ethyl acetate (50 ml) was added to each reaction mixture,
and the solution was washed with saturated NaHCO3 (2 3 30 ml)
and brine. The organic layers were dried over anhydrous MgSO4
and concentrated under reduced pressure. The desired compounds
were obtained pure by silica gel chromatography with yields ranging
from 51% to 71% (CH2Cl2:THF, 10:1–15:1, vv) and were character-
ized by MALDI mass spectrometry (Supplemental Data).
General Procedure for Synthesis of Southern
Peptide Fragments
The Southern dipeptide fragments (B, Figure 2) (position 4 mutants)
were synthesized in solution by using Fmoc-protected amino acids
(1.1 mmol) and H-Phe-OtBu (1.1 mmol) with HBTU (3.3 mmol, 3
equivalents), HOBt (3.3 mmol, 3 equivalents), and DIEA (3.3 mmol,
3 equivalents) in DMF (10 ml) at room temperature for 2 hr. The reac-
tion mixtures were washed with 10% citric acid (23 50 ml), saturated
NaHCO3 (2 3 50 ml), and brine. The organic layers were dried over
anhydrous MgSO4 and concentrated in vacuo. The resulting ma-
terials were filtered through a short pad of silica gel (5 cm) with
hexane:ethyl acetate (1:1), and the solutions were concentrated in
vacuo. The residues were treated with 20% piperidine in DMF
(3 ml) for 30 min at room temperature, the solutions were concen-
trated in vacuo, and the desired products were purified on silica
gel (1:1 hexane:ethyl acetate, v/v to 1:10 MeOH:CH2Cl2, v/v). The re-
sulting compounds were treated with a solution of TFA and H2O
(95:5, 4 ml) at room temperature for 2 hr. The reaction mixtures
were concentrated in vacuo, and the desired materials were purified
to homogeneity by reverse-phase HPLC and characterized by ESI
mass spectrometry (Supplemental Data).
The Southern dipeptide fragments (position 5 mutants) were syn-
thesized in solution by using Cbz-Asn-OH (1.1 mmol) and t-butyl-
protected amino acids (1.1 mmol) with HBTU (3.3 mmol, 3 equiv-
alents), HOBt (3.3 mmol, 3 equivalents), and DIEA (3.3 mmol, 3
equivalents) in DMF (10 ml) at room temperature for 2 hr. The solu-
tions were washed with 10% citric acid (2 3 50 ml), saturated
NaHCO3 (2 3 50 ml), and brine. The organic layers were dried over
anhydrous MgSO4 and concentrated in vacuo. The resulting ma-
terials were filtered through a short pad of silica gel (5 cm) withhexane:ethyl acetate (1:1), and the solutions were concentrated
in vacuo. The residues were dissolved in EtOH (15 ml), and Pd/C
(10%) was added. The reaction mixtures were stirred under an atmo-
sphere of H2 at room temperature for 12 hr and filtered through
celite, and the solvents were removed under reduced pressure.
The resulting compounds were treated with a solution of TFA and
H2O (95:5, 4 ml) at room temperature for 2 hr. The reaction mixtures
were concentrated in vacuo, and the desired materials were purified
to homogeneity by reverse-phase HPLC and characterized by ESI
mass spectrometry (Supplemental Data).
General Procedure for the Microtiter Plate Coupling Reaction
The NHS-activated, acylated Northern peptide fragments (A, Fig-
ure 2) (20 ml, 50 mM stock solution in DMSO) were added to wells
of a microtiter plate that contained the Southern dipeptides (B, Fig-
ure 2) (20 ml, 200 mM stock solution in DMSO) and DIEA (1.1 ml,
0.0063 mmol) at room temperature. After 12 hr, the reaction mixture
in each tube was diluted to a final concentration of 400 mM with
DMSO, and the mixtures were analyzed for purity by HPLC and char-
acterized by MALDI mass spectrometry (Supplemental Data). Each
stock solution was used directly to obtain inhibitory constants
against HIV-1 PR.
Enzymatic Assays
For the determination of IC50 values, 50 ml HIV-1 PR (50 nM stock so-
lution in pH 5.5 phosphate buffer A containing 10% glycerol, 0.1%
CHAPS, 1 mM EDTA, and 1 mM DTT) was added to the cluster tubes
containing a solution (10 ml) of the appropriate amount of the inhib-
itor stock solution and DMSO. The mixture was incubated at room
temperature for 1 hr, and the substrate (40 ml, 150 mM stock in buffer
A with 10% DMSO) was added to yield a final substrate concentra-
tion of 60 mM. The change in fluorescence at 430 nm (lex 360 nm)
was monitored at 30ºC for 15 min. For determination of Ki values,
all parameters were identical, with the following exceptions: HIV-1
PR concentrations ranged from 5 to 160 nM, and the final substrate
concentration was held at 25 mM. All experiments were performed in
triplicate.
Supplemental Data
Supplemental Data including a list of compound characterizations
and inhibitory activity (IC50 values) for purified and in situ-generated
inhibitors are available at http://www.chembiol.com/cgi/content/
full/13/4/421/DC1/.
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